Endoluminal treatment for venous vascular complications of malignant tumors

Xiao,Liang; Tong,Jia-Jie; Shen,Jing

doi:10.3892/etm.2012.589

Endoluminal treatment for venous vascular complications of malignant tumors

Authors:
- Liang Xiao
- Jia-Jie Tong
- Jing Shen
View Affiliations

Affiliations: Department of Radiology, First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: May 24, 2012 https://doi.org/10.3892/etm.2012.589
Pages: 323-328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the efficacy and safety of interventional treatment for venous vascular complications of malignant tumors. Sixty-one patients with venous vascular complications of malignant tumors were treated from May 2002 to May 2009; 37 men and 24 women with mean age 57.8 years (33-82 years). Lesions included acute deep vein thrombosis (n=18); venous stenosis or occlusion (n=32); tumor embolus in vein (n=11). The interventional therapeutic operations included vena cava filter implantation, transcatheter thrombolytic therapy, recanalization, percutaneous transluminal angioplasty (PTA) and stenting. The success rate of thrombolysis and stent implantation, the clinical success rate, complications, recurrence rate of the treated region and survival duration were recorded. Eighteen patients accepted filter and thrombolytic therapy with a success rate of 100%; total urokinase dosage was 7.42±1.49 (4.5-10) million units. Symptoms disappeared (n=15), were palliated (n=3) and thrombi were completely dissolved (n=2), almost completely dissolved (n=8, >90%), partially dissolved (n=6, 50-90%) and not dissolved (n=2, <50%). No pulmonary embolism emerged after the operation. Forty-three patients accepted recanalization, PTA and stent therapy with a success rate of 95.3% (41/43). Symptoms disappeared (n=25), were palliated (n=16) and did not change (n=2) 3 days following the operation. There were no severe complications during the procedure. During follow-up, 12 patients again suffered symptoms of venous occlusion and 47 patients died of tumor aggravation without symptom recurrence. As a result, interventional therapy has advantages including smaller injuries, well tolerance, high success rate, quick palliation of symptoms and superior clinical efficacy in the treatment of venous vascular complications for malignant tumors.

View Figures

View References

1.	Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N and Haughton SH: Catheter-directed thrombolysis for lower extremity deep venous thrombolysis: report of a national multicenter registry. Radiology. 211:39–49. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP and Dake MD: Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 206:187–193. 1998. View Article : Google Scholar : PubMed/NCBI
3.	AbuRahma A and Robinson PA: Effort subclavian vein thrombosis: evolution of management. J Endovasc Ther. 7:302–308. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Kreienberg PB, Chang BB, Darling RC III, et al: Long-term results in patients with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. J Vasc Surg. 33:S100–S105. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE and Comerota AJ; American College of Chest Physicians: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians - evidence-based clinical practice guidelines, 8th edition. Chest. 133:S454–S545. 2008. View Article : Google Scholar
6.	Furui S, Sawada S, Kuramoto K, et al: Gianturco stent placement in malignant caval obstruction: analysis of factors for predicting the outcome. Radiology. 195:147–152. 1995. View Article : Google Scholar : PubMed/NCBI
7.	Fletcher WS, Lakin PC, Prommier RF and Wilmarth T: Results of treatment of inferior vena cava syndrome with expandable metallic stents. Arch Surg. 133:935–938. 1998. View Article : Google Scholar : PubMed/NCBI
8.	Lanciego C, Chacon JL, Julian A, et al: Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgnenol. 177:585–593. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Lanciego C, Pangua C, Chacón JI, et al: Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgnenol. 193:549–558. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Nagata T, Makutani S, Uchida H, et al: Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol. 30:959–967. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Kim HS, Preece SR, Black JH, Pham LD and Streiff MB: Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg. 47:388–394. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Maleux G, Marchal P, Palmers M, et al: Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer. Eur Radiol. 20:2293–2300. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Heymans S, Verhaeghe R, Stockx L and Collen D: Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis. Thromb Haemost. 79:517–519. 1998.PubMed/NCBI
14.	Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG and Büller HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 18:3078–3083. 2000.
15.	Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thrombo-embolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 100:3484–3488. 2002. View Article : Google Scholar
16.	Nicholson AA, Ettles DF, Arnold A, Greenstone M and Dyet JF: Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol. 8:781–788. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Miller JH, McBride K, Little F and Price A: Malignant superior vena cava obstruction: stent placement via the subclavian route. Cardiovasc Intervent Radiol. 23:155–158. 2000. View Article : Google Scholar : PubMed/NCBI
18.	de Gregorio Ariza MA, Gamboa P, Gimeno MJ, et al: Percutaneous treatment of superior vena cava syndrome using metallic stents. Eur Radiol. 13:853–862. 2003.PubMed/NCBI
19.	Stambo GW, Leto J, Van Epps K, Woeste T and George C: Endovascular treatment of intrahepatic inferior vena cava obstruction from malignant hepatocellular tumor thrombus utilizing Luminexx self-expanding nitinol stents. South Med J. 99:1148–1149. 2006. View Article : Google Scholar
20.	Zamora CA, Sugimoto K, Mori T, et al: Use of the wallstent for symptomatic relief of malignant inferior vena cava obstructions. Radiat Med. 23:380–385. 2005.PubMed/NCBI
21.	Kishi K, Sonomura T, Fujimoto H, et al: Physiologic effect of stent therapy for inferior vena cava obstruction due to malignant liver tumor. Cardiovasc Intervent Radiol. 29:75–83. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Nio Y, Iguchi C, Itakura M, et al: Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. Anticancer Res. 29:3329–3335. 2009.PubMed/NCBI
23.	Novellas S, Denys A, Bize P, et al: Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol. 32:462–470. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Kishi K, Sonomura T, Mitsuzane K, et al: Self-expandable metallic stent therapy for superior vena cava syndrome: Clinical observations. Radiology. 189:531–535. 1993. View Article : Google Scholar : PubMed/NCBI
25.	Smayra T, Otal P, Chabbert V, et al: Long-term results of endovascular stent placement in the superior cava venous system. Cardiovasc Intervent Radiol. 24:388–394. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Smith SL, Manhire AR and Clark DM: Delayed spontaneous superior vena cava perforation associated with a SVC Wallstent. Cardiovasc Intervent Radiol. 24:286–287. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Dinkel HP, Mettke B, Schmid F, Baumgartner I, Triller J and Do DD: Endovascular treatment of malignant superior vena cava syndrome: Is bilateral Wallstent placement superior to unilateral placement? J Endovasc Ther. 10:788–797. 2003. View Article : Google Scholar : PubMed/NCBI